RxDoctor Payments DataLook up a doctor →

Donna Hamill

Primary Care · Grosse Pointe, MINPI 1992108641

Payments from drug & device makers

$16,570in general payments, 2019–2025

Across 494 payments — averaging $33.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Zealand Pharma US, Inc.$2K
  • Lilly USA, LLC$1K
  • Medtronic$1K
  • Sanofi-aventis U.S. LLC$1K
  • Abbott$1K
  • plus $8K from 46 others

What the payments were for

  • Speaking & faculty fees$1,60010%
  • Food & beverage$14,89290%
  • Education$280%
  • Other$500%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,570 in reported general payments places this provider in the 95th percentile of 292 primary care providers in Michigan.

See all primary care providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide309$477,875
OzempicSemaglutide176$322,754
JardianceEmpagliflozin155$201,366
Tresiba Flextouch U-200Insulin Degludec51$104,679
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog65$98,359
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/757$82,792
TrulicityDulaglutide49$79,034
FarxigaDapagliflozin Propanediol63$74,801
Humalog Kwikpen U-200Insulin Lispro24$54,409
Synjardy XrEmpagliflozin/Metformin Hcl26$44,008
SynjardyEmpagliflozin/Metformin Hcl25$31,813
Novolog FlexpenInsulin Aspart83$31,535
Lantus SolostarInsulin Glargine,hum.Rec.Anlog130$26,853
Humulin R U-500Insulin Regular, Human14$24,833
NovologInsulin Aspart58$23,808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$1,424$580,041424 claims
Novo NordiskOzempic, Novolog$1,825$346,562234 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy$601$277,188206 claims
AstraZenecaFarxiga$614$74,80163 claims
Johnson & JohnsonInvokana$23$12,89918 claims
Sanofi-aventis U.S. LLCLantus$1,206$2,46512 claims
AbbVieSynthroid$181$1,27018 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$223$76366 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 primary care providers in Michigan.

Other primary care in Grosse Pointe

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →